A phase Ia/b, open-label, multicentre study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers

被引：0

作者：

Harding, J. J. ^{[1
]}

Hofheinz, R. D. ^{[2
]}

Fernandez, M. E. Elez ^{[3
]}

Kuboki, Y. ^{[4
]}

Rasco, D. ^{[5
]}

Cecchini, M. ^{[6
]}

Shen, L. ^{[7
]}

Archuadze, S. ^{[8
]}

Geng, J. ^{[9
]}

Haderk, F. ^{[10
]}

Pant, S. ^{[11
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA

[2] Univ Mannheim, Tagestherapiezentrum UMM, Mannheim, Germany

[3] Vall Hebron Univ Hosp, Dept Med Oncol, Barcelona, Spain

[4] Natl Canc Ctr Hosp East, Dept Expt Therapeut & GI Oncol, Kashiwa, Chiba, Japan

[5] Ctr Canc Care, START, San Antonio, TX USA

[6] Yale Univ, Yale Canc Ctr, New Haven, CT USA

[7] Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Beijing, Peoples R China

[8] Boehringer Ingelheim GmbH & Co KG, Therapeut Area Med Oncol, Ingelheim, Germany

[9] Boehringer Ingelheim GmbH & Co KG, Biostatist & Data Sci, Ridgefield, CT USA

[10] Boehringer Ingelheim GmbH & Co KG, Translat Med & Clin Pharmacol, Biberach, Germany

[11] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA

来源：

关键词：

D O I：

10.1016/j.annonc.2022.07.509

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

371P

引用

页码：S706 / S706

页数：1